|
|
|
| Comparison of application effect of three therapies in Helicobacter pylori positive patients |
| XU Chunbo |
| Department of Gastroenterology, Tongzhou District People′s Hospital, Jiangsu Province, Nantong 226300, China |
|
|
|
|
Abstract Objective To explore the application effect of bismuth containing quadruple therapy, sequential therapy and concomitant therapy in Helicobacter pylori (Hp) positive patients. Methods A total of 127 patients with peptic ulcer and chronic gastritis treated in Tongzhou District People′s Hospital of Nantong city from March 2019 to March 2021 were selected as the research subjects. All patients were confirmed by gastroscopy and positive for Hp by 14C urea breath test. According to random number table method, they were divided into bismuth quadruple therapy group (n=43),sequential therapy group (n=42) and companion therapy group (n=42). Hp eradication rate, improvement of clinical symptoms and total incidence of adverse reactions were compared among three groups after treatment. Results The results of intentional analysis showed that the Hp eradication rates of the sequential therapy group, the bismuth quadruple group and the companion therapy group were 69.05%, 79.07% and 85.71%, respectively. There was no statistical significance in the Hp eradication rates of the three groups (P>0.05). According to the results of the protocol set, the Hp eradication rates of the sequential therapy group, the bismuth quadruple therapy group and the companion therapy group were 73.68%, 87.5% and 94.87%, respectively, and the difference of Hp eradication rates among three groups were statistically significant (P<0.05). The Hp eradication rate in the companion therapy group was higher than that in the sequential therapy group, and the difference was statistically significant (P<0.017). There was no statistical significance in symptom scores of the three groups before treatment (P>0.05). After treatment, the symptom scores of patients in the three groups were higher than before, the difference was statistically significant (P<0.05), but there was no statistically significant difference between the symptom scores of patients in the three groups (P>0.05). The total incidence of adverse reactions after treatment was 19.05% (8/42) in the sequential treatment group, 16.28% (7/43) in the bismuth quadruple therapy group and 38.1% (16/42) in the companion treatment group, respectively, and there was no significant difference in the total incidence of adverse reactions among the three groups (P>0.05). Conclusion Companion therapy had the best Hp eradication rate, and the three treatments had similar symptom improvement effects with high safety.
|
|
|
|
|
|
| [1] |
崔璨璨，李长锋，张斌.幽门螺旋杆菌感染治疗方案的研究现状和进展[J].吉林大学学报（医学版），2017，43（6）：1287-1290.
|
| [2] |
中华医学会消化病学分会幽门螺杆菌和消化性溃疡学组，刘文忠，谢勇，等.第五次全国幽门螺杆菌感染处理共识报告[J].胃肠病学，2017，22（6）：346-360.
|
| [3] |
刘梦真.根除幽门螺旋杆菌影响因素的研究进展[J].医学研究生学报，2019，32（12）：1339-1344.
|
| [4] |
Malfertheiner P，Megraud F，O'Morain CA，et al.Management of Helicobacter pylori infection-the Maastricht Ⅳ/Florence Consensus Report[J].Gut，2012，61（5）：646-664.
|
| [5] |
殷久勇.序贯疗法与四联疗法治疗幽门螺杆菌感染性胃溃疡的临床对照研究[J].江西医药，2021，56（10）：1735-1738.
|
| [6] |
中华医学会消化病学分会.中国慢性胃炎共识意见（2017年，上海）[J].中华消化杂志，2017，37（11）：721-738.
|
| [7] |
中华消化杂志编委会.消化性溃疡诊断与治疗规范（2016年，西安）[J].中华消化杂志，2016，36（8）：508-513.
|
| [8] |
田英.探讨益生菌联合铋剂四联治疗Hp 阳性慢性胃炎患者的临床疗效与安全性[J].中国医师杂志，2019，21（4）：601-603.
|
| [9] |
叶剑芳，洪军波，胡奕，等.幽门螺杆菌感染的复发及其影响因素[J].中华内科杂志，2018，57（3）：223-225.
|
| [10] |
袁龙良，辛毅，王启之.幽门螺旋杆菌根除失败的影响因素分析[J].蚌埠医学院学报，2019，44（11）：1497-1499.
|
| [11] |
Hao Q，Li Y，Zhang ZJ，et al.New mutation points in 23S rRNA gene associated with Helicobacter pylori resistance to clarithromycin in northeast China[J].World J Gastroenterol，2004，10：1075-1077.
|
| [12] |
罗红春，吕琳，杨致邦，等.重庆地区分离幽门螺杆菌对克拉霉素耐药性研究[J].重庆医科大学学报，2009，34（8）：1077-1080.
|
| [13] |
蒋晓玲，袁蕙芸.我国幽门螺杆菌感染处理共识推荐的铋剂四联方案根除率分析[J].胃肠病学，2014（9）：531-536.
|
| [14] |
谭嘉圣，李伊倩，陈毅斌.序贯疗法与标准三联疗法治疗幽门螺杆菌相关性胃炎的疗效评价[J].当代医学，2022，28（1）：160-162.
|
| [15] |
苗慧.序贯疗法与常规四联疗法治疗幽门螺杆菌阳性消化性溃疡患者的效果比较[J].中国民康医学，2021，33（10）：123-125.
|
| [16] |
梁辰飞，宋志强，周丽雅.伴同疗法根除幽门螺杆菌感染的相关研究现状[J].临床消化病杂志，2014，26（2）：119-122.
|
| [17] |
Jafri NS，Hornung CA，Howden CW.Meta-analysis：sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment[J].Ann Intern Med，2008，148（12）：923-931.
|
| [18] |
Qian J，Ye F，Zhang J，et al.Levofloxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China[J].Helicobacter，2012，17（6）：478-485
|
|
|
|
